nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—PGR—breast cancer	0.104	0.346	CbGaD
Etonogestrel—SHBG—breast cancer	0.0972	0.324	CbGaD
Etonogestrel—SHBG—Fluoxymesterone—breast cancer	0.0724	0.218	CbGbCtD
Etonogestrel—ESR1—breast cancer	0.0656	0.219	CbGaD
Etonogestrel—ESR1—Fluoxymesterone—breast cancer	0.0523	0.158	CbGbCtD
Etonogestrel—ESR1—Toremifene—breast cancer	0.0523	0.158	CbGbCtD
Etonogestrel—ESR1—Fulvestrant—breast cancer	0.0487	0.146	CbGbCtD
Etonogestrel—Danazol—Fluoxymesterone—breast cancer	0.0483	0.242	CrCrCtD
Etonogestrel—Testosterone—Exemestane—breast cancer	0.0443	0.222	CrCrCtD
Etonogestrel—Norethindrone—Fluoxymesterone—breast cancer	0.042	0.21	CrCrCtD
Etonogestrel—Methyltestosterone—Fluoxymesterone—breast cancer	0.0345	0.173	CrCrCtD
Etonogestrel—CYP3A4—breast cancer	0.0335	0.112	CbGaD
Etonogestrel—Testosterone—Fluoxymesterone—breast cancer	0.0307	0.154	CrCrCtD
Etonogestrel—ESR1—Raloxifene—breast cancer	0.0289	0.0871	CbGbCtD
Etonogestrel—ESR1—Tamoxifen—breast cancer	0.0191	0.0576	CbGbCtD
Etonogestrel—CYP3A4—Exemestane—breast cancer	0.00776	0.0233	CbGbCtD
Etonogestrel—CYP3A4—Letrozole—breast cancer	0.00659	0.0199	CbGbCtD
Etonogestrel—PGR—corpus luteum—breast cancer	0.0062	0.298	CbGeAlD
Etonogestrel—CYP3A4—Anastrozole—breast cancer	0.00588	0.0177	CbGbCtD
Etonogestrel—CYP3A4—Toremifene—breast cancer	0.00538	0.0162	CbGbCtD
Etonogestrel—CYP3A4—Fulvestrant—breast cancer	0.005	0.015	CbGbCtD
Etonogestrel—CYP3A4—Thiotepa—breast cancer	0.00445	0.0134	CbGbCtD
Etonogestrel—CYP3A4—Ixabepilone—breast cancer	0.00407	0.0123	CbGbCtD
Etonogestrel—CYP3A4—Lapatinib—breast cancer	0.00392	0.0118	CbGbCtD
Etonogestrel—CYP3A4—Raloxifene—breast cancer	0.00297	0.00895	CbGbCtD
Etonogestrel—CYP3A4—Vinorelbine—breast cancer	0.00218	0.00655	CbGbCtD
Etonogestrel—CYP3A4—Tamoxifen—breast cancer	0.00196	0.00591	CbGbCtD
Etonogestrel—CYP3A4—Mitoxantrone—breast cancer	0.00192	0.00577	CbGbCtD
Etonogestrel—CYP3A4—Paclitaxel—breast cancer	0.00153	0.0046	CbGbCtD
Etonogestrel—CYP3A4—Irinotecan—breast cancer	0.00151	0.00454	CbGbCtD
Etonogestrel—CYP3A4—Vinblastine—breast cancer	0.00134	0.00404	CbGbCtD
Etonogestrel—CYP3A4—Docetaxel—breast cancer	0.0011	0.00333	CbGbCtD
Etonogestrel—PGR—mammary gland—breast cancer	0.00096	0.0462	CbGeAlD
Etonogestrel—CYP3A4—Doxorubicin—breast cancer	0.000824	0.00248	CbGbCtD
Etonogestrel—PGR—nipple—breast cancer	0.000794	0.0382	CbGeAlD
Etonogestrel—ESR1—mammary gland—breast cancer	0.000751	0.0361	CbGeAlD
Etonogestrel—PGR—epithelium—breast cancer	0.000535	0.0257	CbGeAlD
Etonogestrel—SHBG—endometrium—breast cancer	0.000532	0.0256	CbGeAlD
Etonogestrel—ESR1—embryo—breast cancer	0.000513	0.0247	CbGeAlD
Etonogestrel—SHBG—uterus—breast cancer	0.000491	0.0236	CbGeAlD
Etonogestrel—SHBG—pituitary gland—breast cancer	0.000482	0.0232	CbGeAlD
Etonogestrel—SHBG—adipose tissue—breast cancer	0.00048	0.0231	CbGeAlD
Etonogestrel—PGR—endometrium—breast cancer	0.00048	0.0231	CbGeAlD
Etonogestrel—PGR—uterus—breast cancer	0.000442	0.0213	CbGeAlD
Etonogestrel—SHBG—female reproductive system—breast cancer	0.000441	0.0212	CbGeAlD
Etonogestrel—PGR—pituitary gland—breast cancer	0.000434	0.0209	CbGeAlD
Etonogestrel—PGR—adipose tissue—breast cancer	0.000432	0.0208	CbGeAlD
Etonogestrel—SHBG—adrenal gland—breast cancer	0.00043	0.0207	CbGeAlD
Etonogestrel—ESR1—epithelium—breast cancer	0.000418	0.0201	CbGeAlD
Etonogestrel—SHBG—bone marrow—breast cancer	0.000416	0.02	CbGeAlD
Etonogestrel—SHBG—female gonad—breast cancer	0.000401	0.0193	CbGeAlD
Etonogestrel—PGR—female reproductive system—breast cancer	0.000397	0.0191	CbGeAlD
Etonogestrel—PGR—adrenal gland—breast cancer	0.000388	0.0187	CbGeAlD
Etonogestrel—ESR1—endometrium—breast cancer	0.000375	0.0181	CbGeAlD
Etonogestrel—SHBG—endocrine gland—breast cancer	0.000373	0.018	CbGeAlD
Etonogestrel—PGR—female gonad—breast cancer	0.000362	0.0174	CbGeAlD
Etonogestrel—ESR1—uterus—breast cancer	0.000346	0.0166	CbGeAlD
Etonogestrel—ESR1—pituitary gland—breast cancer	0.000339	0.0163	CbGeAlD
Etonogestrel—ESR1—adipose tissue—breast cancer	0.000338	0.0163	CbGeAlD
Etonogestrel—PGR—endocrine gland—breast cancer	0.000336	0.0162	CbGeAlD
Etonogestrel—ESR1—female reproductive system—breast cancer	0.000311	0.015	CbGeAlD
Etonogestrel—ESR1—adrenal gland—breast cancer	0.000303	0.0146	CbGeAlD
Etonogestrel—ESR1—female gonad—breast cancer	0.000283	0.0136	CbGeAlD
Etonogestrel—ESR1—endocrine gland—breast cancer	0.000263	0.0127	CbGeAlD
Etonogestrel—PGR—lymph node—breast cancer	0.000232	0.0112	CbGeAlD
Etonogestrel—ESR1—lymph node—breast cancer	0.000182	0.00875	CbGeAlD
Etonogestrel—CYP3A4—female reproductive system—breast cancer	0.000173	0.00834	CbGeAlD
Etonogestrel—CYP3A4—endocrine gland—breast cancer	0.000147	0.00706	CbGeAlD
Etonogestrel—Norelgestromin—PGR—breast cancer	0.000145	0.052	CrCbGaD
Etonogestrel—Desogestrel—PGR—breast cancer	0.00014	0.05	CrCbGaD
Etonogestrel—Norgestimate—PGR—breast cancer	0.000131	0.0468	CrCbGaD
Etonogestrel—Desogestrel—SHBG—breast cancer	0.000131	0.0468	CrCbGaD
Etonogestrel—Nandrolone phenpropionate—AR—breast cancer	0.00013	0.0466	CrCbGaD
Etonogestrel—Quinestrol—ESR1—breast cancer	0.000118	0.0422	CrCbGaD
Etonogestrel—Nandrolone phenpropionate—CYP19A1—breast cancer	0.000109	0.039	CrCbGaD
Etonogestrel—Nandrolone decanoate—AR—breast cancer	9.86e-05	0.0353	CrCbGaD
Etonogestrel—Mestranol—ESR1—breast cancer	8.94e-05	0.032	CrCbGaD
Etonogestrel—Desogestrel—ESR1—breast cancer	8.83e-05	0.0316	CrCbGaD
Etonogestrel—Nandrolone decanoate—CYP19A1—breast cancer	8.26e-05	0.0296	CrCbGaD
Etonogestrel—Norgestimate—ESR1—breast cancer	8.26e-05	0.0296	CrCbGaD
Etonogestrel—Levonorgestrel—PGR—breast cancer	8.01e-05	0.0287	CrCbGaD
Etonogestrel—Levonorgestrel—SHBG—breast cancer	7.48e-05	0.0268	CrCbGaD
Etonogestrel—Danazol—PGR—breast cancer	7.29e-05	0.0261	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ESR2—breast cancer	6.91e-05	0.0247	CrCbGaD
Etonogestrel—Danazol—SHBG—breast cancer	6.82e-05	0.0244	CrCbGaD
Etonogestrel—Levonorgestrel—AR—breast cancer	6.56e-05	0.0235	CrCbGaD
Etonogestrel—Norethindrone—PGR—breast cancer	6.49e-05	0.0232	CrCbGaD
Etonogestrel—Ethinyl Estradiol—SHBG—breast cancer	6.31e-05	0.0226	CrCbGaD
Etonogestrel—Norethindrone—SHBG—breast cancer	6.06e-05	0.0217	CrCbGaD
Etonogestrel—Danazol—AR—breast cancer	5.98e-05	0.0214	CrCbGaD
Etonogestrel—Methyltestosterone—SHBG—breast cancer	5.76e-05	0.0206	CrCbGaD
Etonogestrel—Levonorgestrel—CYP19A1—breast cancer	5.49e-05	0.0197	CrCbGaD
Etonogestrel—Levonorgestrel—ESR1—breast cancer	5.05e-05	0.0181	CrCbGaD
Etonogestrel—Methyltestosterone—AR—breast cancer	5.05e-05	0.0181	CrCbGaD
Etonogestrel—Danazol—CYP19A1—breast cancer	5e-05	0.0179	CrCbGaD
Etonogestrel—Danazol—ESR1—breast cancer	4.6e-05	0.0165	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ESR1—breast cancer	4.26e-05	0.0152	CrCbGaD
Etonogestrel—Methyltestosterone—CYP19A1—breast cancer	4.23e-05	0.0151	CrCbGaD
Etonogestrel—Testosterone—SHBG—breast cancer	3.34e-05	0.012	CrCbGaD
Etonogestrel—Testosterone—CYP1B1—breast cancer	3.34e-05	0.012	CrCbGaD
Etonogestrel—Testosterone—AR—breast cancer	2.93e-05	0.0105	CrCbGaD
Etonogestrel—Levonorgestrel—CYP3A4—breast cancer	2.58e-05	0.00923	CrCbGaD
Etonogestrel—Testosterone—CYP19A1—breast cancer	2.45e-05	0.00878	CrCbGaD
Etonogestrel—Danazol—CYP3A4—breast cancer	2.35e-05	0.00841	CrCbGaD
Etonogestrel—Testosterone—ABCG2—breast cancer	2.3e-05	0.00824	CrCbGaD
Etonogestrel—Ethinyl Estradiol—CYP3A4—breast cancer	2.17e-05	0.00778	CrCbGaD
Etonogestrel—Norethindrone—CYP3A4—breast cancer	2.09e-05	0.00748	CrCbGaD
Etonogestrel—Methyltestosterone—CYP3A4—breast cancer	1.99e-05	0.00711	CrCbGaD
Etonogestrel—Norethindrone—ALB—breast cancer	1.82e-05	0.00653	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ABCB1—breast cancer	1.81e-05	0.00648	CrCbGaD
Etonogestrel—Testosterone—CYP1A1—breast cancer	1.8e-05	0.00646	CrCbGaD
Etonogestrel—Hypoaesthesia—Epirubicin—breast cancer	1.77e-05	0.000181	CcSEcCtD
Etonogestrel—Pharyngitis—Epirubicin—breast cancer	1.77e-05	0.00018	CcSEcCtD
Etonogestrel—Skin disorder—Capecitabine—breast cancer	1.76e-05	0.00018	CcSEcCtD
Etonogestrel—Urinary tract disorder—Epirubicin—breast cancer	1.76e-05	0.00018	CcSEcCtD
Etonogestrel—Urticaria—Paclitaxel—breast cancer	1.76e-05	0.00018	CcSEcCtD
Etonogestrel—Connective tissue disorder—Epirubicin—breast cancer	1.75e-05	0.000179	CcSEcCtD
Etonogestrel—Abdominal pain—Paclitaxel—breast cancer	1.75e-05	0.000179	CcSEcCtD
Etonogestrel—Body temperature increased—Paclitaxel—breast cancer	1.75e-05	0.000179	CcSEcCtD
Etonogestrel—Urethral disorder—Epirubicin—breast cancer	1.75e-05	0.000178	CcSEcCtD
Etonogestrel—Norethindrone—ABCB1—breast cancer	1.74e-05	0.00623	CrCbGaD
Etonogestrel—Methyltestosterone—ALB—breast cancer	1.73e-05	0.0062	CrCbGaD
Etonogestrel—Anorexia—Capecitabine—breast cancer	1.73e-05	0.000177	CcSEcCtD
Etonogestrel—Angiopathy—Methotrexate—breast cancer	1.73e-05	0.000176	CcSEcCtD
Etonogestrel—Vomiting—Irinotecan—breast cancer	1.73e-05	0.000176	CcSEcCtD
Etonogestrel—Vomiting—Mitoxantrone—breast cancer	1.73e-05	0.000176	CcSEcCtD
Etonogestrel—Sinusitis—Doxorubicin—breast cancer	1.72e-05	0.000176	CcSEcCtD
Etonogestrel—Immune system disorder—Methotrexate—breast cancer	1.72e-05	0.000176	CcSEcCtD
Etonogestrel—Dizziness—Fluorouracil—breast cancer	1.72e-05	0.000176	CcSEcCtD
Etonogestrel—Visual impairment—Epirubicin—breast cancer	1.72e-05	0.000175	CcSEcCtD
Etonogestrel—Rash—Mitoxantrone—breast cancer	1.71e-05	0.000175	CcSEcCtD
Etonogestrel—Rash—Irinotecan—breast cancer	1.71e-05	0.000175	CcSEcCtD
Etonogestrel—Dermatitis—Mitoxantrone—breast cancer	1.71e-05	0.000175	CcSEcCtD
Etonogestrel—Dermatitis—Irinotecan—breast cancer	1.71e-05	0.000175	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Docetaxel—breast cancer	1.71e-05	0.000175	CcSEcCtD
Etonogestrel—Headache—Mitoxantrone—breast cancer	1.7e-05	0.000174	CcSEcCtD
Etonogestrel—Headache—Irinotecan—breast cancer	1.7e-05	0.000174	CcSEcCtD
Etonogestrel—Insomnia—Docetaxel—breast cancer	1.7e-05	0.000173	CcSEcCtD
Etonogestrel—Paraesthesia—Docetaxel—breast cancer	1.68e-05	0.000172	CcSEcCtD
Etonogestrel—Alopecia—Methotrexate—breast cancer	1.68e-05	0.000172	CcSEcCtD
Etonogestrel—Vomiting—Gemcitabine—breast cancer	1.68e-05	0.000172	CcSEcCtD
Etonogestrel—Somnolence—Docetaxel—breast cancer	1.67e-05	0.00017	CcSEcCtD
Etonogestrel—Mental disorder—Methotrexate—breast cancer	1.67e-05	0.00017	CcSEcCtD
Etonogestrel—Rash—Gemcitabine—breast cancer	1.67e-05	0.00017	CcSEcCtD
Etonogestrel—Dermatitis—Gemcitabine—breast cancer	1.67e-05	0.00017	CcSEcCtD
Etonogestrel—Eye disorder—Epirubicin—breast cancer	1.66e-05	0.00017	CcSEcCtD
Etonogestrel—Erythema—Methotrexate—breast cancer	1.66e-05	0.000169	CcSEcCtD
Etonogestrel—Malnutrition—Methotrexate—breast cancer	1.66e-05	0.000169	CcSEcCtD
Etonogestrel—Haemoglobin—Doxorubicin—breast cancer	1.66e-05	0.000169	CcSEcCtD
Etonogestrel—Headache—Gemcitabine—breast cancer	1.66e-05	0.000169	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Capecitabine—breast cancer	1.65e-05	0.000169	CcSEcCtD
Etonogestrel—Vomiting—Fluorouracil—breast cancer	1.65e-05	0.000169	CcSEcCtD
Etonogestrel—Rhinitis—Doxorubicin—breast cancer	1.65e-05	0.000169	CcSEcCtD
Etonogestrel—Dyspepsia—Docetaxel—breast cancer	1.65e-05	0.000169	CcSEcCtD
Etonogestrel—Haemorrhage—Doxorubicin—breast cancer	1.65e-05	0.000168	CcSEcCtD
Etonogestrel—Insomnia—Capecitabine—breast cancer	1.64e-05	0.000168	CcSEcCtD
Etonogestrel—Hypoaesthesia—Doxorubicin—breast cancer	1.64e-05	0.000167	CcSEcCtD
Etonogestrel—Rash—Fluorouracil—breast cancer	1.64e-05	0.000167	CcSEcCtD
Etonogestrel—Dermatitis—Fluorouracil—breast cancer	1.64e-05	0.000167	CcSEcCtD
Etonogestrel—Pharyngitis—Doxorubicin—breast cancer	1.64e-05	0.000167	CcSEcCtD
Etonogestrel—Paraesthesia—Capecitabine—breast cancer	1.63e-05	0.000167	CcSEcCtD
Etonogestrel—Decreased appetite—Docetaxel—breast cancer	1.63e-05	0.000167	CcSEcCtD
Etonogestrel—Hypersensitivity—Paclitaxel—breast cancer	1.63e-05	0.000167	CcSEcCtD
Etonogestrel—Headache—Fluorouracil—breast cancer	1.63e-05	0.000166	CcSEcCtD
Etonogestrel—Urinary tract disorder—Doxorubicin—breast cancer	1.63e-05	0.000166	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Docetaxel—breast cancer	1.62e-05	0.000165	CcSEcCtD
Etonogestrel—Connective tissue disorder—Doxorubicin—breast cancer	1.62e-05	0.000165	CcSEcCtD
Etonogestrel—Fatigue—Docetaxel—breast cancer	1.62e-05	0.000165	CcSEcCtD
Etonogestrel—Angiopathy—Epirubicin—breast cancer	1.62e-05	0.000165	CcSEcCtD
Etonogestrel—Urethral disorder—Doxorubicin—breast cancer	1.62e-05	0.000165	CcSEcCtD
Etonogestrel—Nausea—Irinotecan—breast cancer	1.61e-05	0.000165	CcSEcCtD
Etonogestrel—Nausea—Mitoxantrone—breast cancer	1.61e-05	0.000165	CcSEcCtD
Etonogestrel—Immune system disorder—Epirubicin—breast cancer	1.61e-05	0.000164	CcSEcCtD
Etonogestrel—Pain—Docetaxel—breast cancer	1.6e-05	0.000164	CcSEcCtD
Etonogestrel—Constipation—Docetaxel—breast cancer	1.6e-05	0.000164	CcSEcCtD
Etonogestrel—Back pain—Methotrexate—breast cancer	1.6e-05	0.000164	CcSEcCtD
Etonogestrel—Dyspepsia—Capecitabine—breast cancer	1.6e-05	0.000163	CcSEcCtD
Etonogestrel—Visual impairment—Doxorubicin—breast cancer	1.59e-05	0.000162	CcSEcCtD
Etonogestrel—Asthenia—Paclitaxel—breast cancer	1.59e-05	0.000162	CcSEcCtD
Etonogestrel—Decreased appetite—Capecitabine—breast cancer	1.58e-05	0.000161	CcSEcCtD
Etonogestrel—Alopecia—Epirubicin—breast cancer	1.57e-05	0.000161	CcSEcCtD
Etonogestrel—Nausea—Gemcitabine—breast cancer	1.57e-05	0.00016	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Capecitabine—breast cancer	1.57e-05	0.00016	CcSEcCtD
Etonogestrel—Fatigue—Capecitabine—breast cancer	1.57e-05	0.00016	CcSEcCtD
Etonogestrel—Pruritus—Paclitaxel—breast cancer	1.57e-05	0.00016	CcSEcCtD
Etonogestrel—Mental disorder—Epirubicin—breast cancer	1.56e-05	0.000159	CcSEcCtD
Etonogestrel—Pain—Capecitabine—breast cancer	1.55e-05	0.000159	CcSEcCtD
Etonogestrel—Constipation—Capecitabine—breast cancer	1.55e-05	0.000159	CcSEcCtD
Etonogestrel—Malnutrition—Epirubicin—breast cancer	1.55e-05	0.000158	CcSEcCtD
Etonogestrel—Erythema—Epirubicin—breast cancer	1.55e-05	0.000158	CcSEcCtD
Etonogestrel—Feeling abnormal—Docetaxel—breast cancer	1.55e-05	0.000158	CcSEcCtD
Etonogestrel—Nausea—Fluorouracil—breast cancer	1.54e-05	0.000158	CcSEcCtD
Etonogestrel—Eye disorder—Doxorubicin—breast cancer	1.54e-05	0.000157	CcSEcCtD
Etonogestrel—Ill-defined disorder—Methotrexate—breast cancer	1.54e-05	0.000157	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Docetaxel—breast cancer	1.53e-05	0.000157	CcSEcCtD
Etonogestrel—Flatulence—Epirubicin—breast cancer	1.53e-05	0.000156	CcSEcCtD
Etonogestrel—Tension—Epirubicin—breast cancer	1.52e-05	0.000155	CcSEcCtD
Etonogestrel—Diarrhoea—Paclitaxel—breast cancer	1.51e-05	0.000155	CcSEcCtD
Etonogestrel—Nervousness—Epirubicin—breast cancer	1.51e-05	0.000154	CcSEcCtD
Etonogestrel—Back pain—Epirubicin—breast cancer	1.5e-05	0.000153	CcSEcCtD
Etonogestrel—Feeling abnormal—Capecitabine—breast cancer	1.5e-05	0.000153	CcSEcCtD
Etonogestrel—Angiopathy—Doxorubicin—breast cancer	1.5e-05	0.000153	CcSEcCtD
Etonogestrel—Malaise—Methotrexate—breast cancer	1.49e-05	0.000153	CcSEcCtD
Etonogestrel—Muscle spasms—Epirubicin—breast cancer	1.49e-05	0.000152	CcSEcCtD
Etonogestrel—Immune system disorder—Doxorubicin—breast cancer	1.49e-05	0.000152	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Capecitabine—breast cancer	1.49e-05	0.000152	CcSEcCtD
Etonogestrel—Abdominal pain—Docetaxel—breast cancer	1.48e-05	0.000151	CcSEcCtD
Etonogestrel—Body temperature increased—Docetaxel—breast cancer	1.48e-05	0.000151	CcSEcCtD
Etonogestrel—Dizziness—Paclitaxel—breast cancer	1.46e-05	0.000149	CcSEcCtD
Etonogestrel—Alopecia—Doxorubicin—breast cancer	1.46e-05	0.000149	CcSEcCtD
Etonogestrel—Cough—Methotrexate—breast cancer	1.45e-05	0.000148	CcSEcCtD
Etonogestrel—Mental disorder—Doxorubicin—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Urticaria—Capecitabine—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Ill-defined disorder—Epirubicin—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Abdominal pain—Capecitabine—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Body temperature increased—Capecitabine—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Convulsion—Methotrexate—breast cancer	1.44e-05	0.000147	CcSEcCtD
Etonogestrel—Malnutrition—Doxorubicin—breast cancer	1.43e-05	0.000146	CcSEcCtD
Etonogestrel—Erythema—Doxorubicin—breast cancer	1.43e-05	0.000146	CcSEcCtD
Etonogestrel—Flatulence—Doxorubicin—breast cancer	1.41e-05	0.000144	CcSEcCtD
Etonogestrel—Myalgia—Methotrexate—breast cancer	1.41e-05	0.000144	CcSEcCtD
Etonogestrel—Arthralgia—Methotrexate—breast cancer	1.41e-05	0.000144	CcSEcCtD
Etonogestrel—Tension—Doxorubicin—breast cancer	1.41e-05	0.000144	CcSEcCtD
Etonogestrel—Vomiting—Paclitaxel—breast cancer	1.41e-05	0.000144	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.4e-05	0.000143	CcSEcCtD
Etonogestrel—Malaise—Epirubicin—breast cancer	1.4e-05	0.000143	CcSEcCtD
Etonogestrel—Rash—Paclitaxel—breast cancer	1.4e-05	0.000142	CcSEcCtD
Etonogestrel—Dermatitis—Paclitaxel—breast cancer	1.39e-05	0.000142	CcSEcCtD
Etonogestrel—Discomfort—Methotrexate—breast cancer	1.39e-05	0.000142	CcSEcCtD
Etonogestrel—Nervousness—Doxorubicin—breast cancer	1.39e-05	0.000142	CcSEcCtD
Etonogestrel—Back pain—Doxorubicin—breast cancer	1.39e-05	0.000142	CcSEcCtD
Etonogestrel—Headache—Paclitaxel—breast cancer	1.39e-05	0.000142	CcSEcCtD
Etonogestrel—Hypersensitivity—Docetaxel—breast cancer	1.38e-05	0.000141	CcSEcCtD
Etonogestrel—Muscle spasms—Doxorubicin—breast cancer	1.38e-05	0.000141	CcSEcCtD
Etonogestrel—Cough—Epirubicin—breast cancer	1.35e-05	0.000138	CcSEcCtD
Etonogestrel—Anaphylactic shock—Methotrexate—breast cancer	1.35e-05	0.000138	CcSEcCtD
Etonogestrel—Asthenia—Docetaxel—breast cancer	1.35e-05	0.000137	CcSEcCtD
Etonogestrel—Convulsion—Epirubicin—breast cancer	1.34e-05	0.000137	CcSEcCtD
Etonogestrel—Infection—Methotrexate—breast cancer	1.34e-05	0.000137	CcSEcCtD
Etonogestrel—Hypertension—Epirubicin—breast cancer	1.34e-05	0.000137	CcSEcCtD
Etonogestrel—Hypersensitivity—Capecitabine—breast cancer	1.34e-05	0.000137	CcSEcCtD
Etonogestrel—Ill-defined disorder—Doxorubicin—breast cancer	1.33e-05	0.000136	CcSEcCtD
Etonogestrel—Pruritus—Docetaxel—breast cancer	1.33e-05	0.000136	CcSEcCtD
Etonogestrel—Nervous system disorder—Methotrexate—breast cancer	1.33e-05	0.000135	CcSEcCtD
Etonogestrel—Myalgia—Epirubicin—breast cancer	1.32e-05	0.000135	CcSEcCtD
Etonogestrel—Arthralgia—Epirubicin—breast cancer	1.32e-05	0.000135	CcSEcCtD
Etonogestrel—Anxiety—Epirubicin—breast cancer	1.32e-05	0.000134	CcSEcCtD
Etonogestrel—Nausea—Paclitaxel—breast cancer	1.31e-05	0.000134	CcSEcCtD
Etonogestrel—Skin disorder—Methotrexate—breast cancer	1.31e-05	0.000134	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.31e-05	0.000134	CcSEcCtD
Etonogestrel—Discomfort—Epirubicin—breast cancer	1.3e-05	0.000133	CcSEcCtD
Etonogestrel—Asthenia—Capecitabine—breast cancer	1.3e-05	0.000133	CcSEcCtD
Etonogestrel—Malaise—Doxorubicin—breast cancer	1.29e-05	0.000132	CcSEcCtD
Etonogestrel—Anorexia—Methotrexate—breast cancer	1.29e-05	0.000132	CcSEcCtD
Etonogestrel—Pruritus—Capecitabine—breast cancer	1.29e-05	0.000131	CcSEcCtD
Etonogestrel—Diarrhoea—Docetaxel—breast cancer	1.28e-05	0.000131	CcSEcCtD
Etonogestrel—Oedema—Epirubicin—breast cancer	1.27e-05	0.000129	CcSEcCtD
Etonogestrel—Anaphylactic shock—Epirubicin—breast cancer	1.27e-05	0.000129	CcSEcCtD
Etonogestrel—Infection—Epirubicin—breast cancer	1.26e-05	0.000128	CcSEcCtD
Etonogestrel—Cough—Doxorubicin—breast cancer	1.25e-05	0.000128	CcSEcCtD
Etonogestrel—Convulsion—Doxorubicin—breast cancer	1.24e-05	0.000127	CcSEcCtD
Etonogestrel—Diarrhoea—Capecitabine—breast cancer	1.24e-05	0.000127	CcSEcCtD
Etonogestrel—Nervous system disorder—Epirubicin—breast cancer	1.24e-05	0.000127	CcSEcCtD
Etonogestrel—Dizziness—Docetaxel—breast cancer	1.24e-05	0.000127	CcSEcCtD
Etonogestrel—Hypertension—Doxorubicin—breast cancer	1.24e-05	0.000126	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Methotrexate—breast cancer	1.23e-05	0.000126	CcSEcCtD
Etonogestrel—Skin disorder—Epirubicin—breast cancer	1.23e-05	0.000126	CcSEcCtD
Etonogestrel—Insomnia—Methotrexate—breast cancer	1.22e-05	0.000125	CcSEcCtD
Etonogestrel—Arthralgia—Doxorubicin—breast cancer	1.22e-05	0.000125	CcSEcCtD
Etonogestrel—Myalgia—Doxorubicin—breast cancer	1.22e-05	0.000125	CcSEcCtD
Etonogestrel—Anxiety—Doxorubicin—breast cancer	1.22e-05	0.000124	CcSEcCtD
Etonogestrel—Paraesthesia—Methotrexate—breast cancer	1.21e-05	0.000124	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.21e-05	0.000124	CcSEcCtD
Etonogestrel—Discomfort—Doxorubicin—breast cancer	1.21e-05	0.000123	CcSEcCtD
Etonogestrel—Anorexia—Epirubicin—breast cancer	1.21e-05	0.000123	CcSEcCtD
Etonogestrel—Somnolence—Methotrexate—breast cancer	1.2e-05	0.000123	CcSEcCtD
Etonogestrel—Dizziness—Capecitabine—breast cancer	1.2e-05	0.000123	CcSEcCtD
Etonogestrel—Vomiting—Docetaxel—breast cancer	1.19e-05	0.000122	CcSEcCtD
Etonogestrel—Dyspepsia—Methotrexate—breast cancer	1.19e-05	0.000122	CcSEcCtD
Etonogestrel—Rash—Docetaxel—breast cancer	1.18e-05	0.000121	CcSEcCtD
Etonogestrel—Dermatitis—Docetaxel—breast cancer	1.18e-05	0.000121	CcSEcCtD
Etonogestrel—Decreased appetite—Methotrexate—breast cancer	1.18e-05	0.00012	CcSEcCtD
Etonogestrel—Headache—Docetaxel—breast cancer	1.18e-05	0.00012	CcSEcCtD
Etonogestrel—Anaphylactic shock—Doxorubicin—breast cancer	1.17e-05	0.00012	CcSEcCtD
Etonogestrel—Oedema—Doxorubicin—breast cancer	1.17e-05	0.00012	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Methotrexate—breast cancer	1.17e-05	0.000119	CcSEcCtD
Etonogestrel—Fatigue—Methotrexate—breast cancer	1.17e-05	0.000119	CcSEcCtD
Etonogestrel—Infection—Doxorubicin—breast cancer	1.16e-05	0.000119	CcSEcCtD
Etonogestrel—Pain—Methotrexate—breast cancer	1.16e-05	0.000118	CcSEcCtD
Etonogestrel—Vomiting—Capecitabine—breast cancer	1.15e-05	0.000118	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Epirubicin—breast cancer	1.15e-05	0.000118	CcSEcCtD
Etonogestrel—Testosterone—CYP3A4—breast cancer	1.15e-05	0.00412	CrCbGaD
Etonogestrel—Nervous system disorder—Doxorubicin—breast cancer	1.15e-05	0.000117	CcSEcCtD
Etonogestrel—Rash—Capecitabine—breast cancer	1.15e-05	0.000117	CcSEcCtD
Etonogestrel—Insomnia—Epirubicin—breast cancer	1.14e-05	0.000117	CcSEcCtD
Etonogestrel—Dermatitis—Capecitabine—breast cancer	1.14e-05	0.000117	CcSEcCtD
Etonogestrel—Headache—Capecitabine—breast cancer	1.14e-05	0.000116	CcSEcCtD
Etonogestrel—Skin disorder—Doxorubicin—breast cancer	1.14e-05	0.000116	CcSEcCtD
Etonogestrel—Paraesthesia—Epirubicin—breast cancer	1.14e-05	0.000116	CcSEcCtD
Etonogestrel—Somnolence—Epirubicin—breast cancer	1.12e-05	0.000115	CcSEcCtD
Etonogestrel—Anorexia—Doxorubicin—breast cancer	1.12e-05	0.000114	CcSEcCtD
Etonogestrel—Nausea—Docetaxel—breast cancer	1.11e-05	0.000114	CcSEcCtD
Etonogestrel—Feeling abnormal—Methotrexate—breast cancer	1.11e-05	0.000114	CcSEcCtD
Etonogestrel—Dyspepsia—Epirubicin—breast cancer	1.11e-05	0.000114	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Methotrexate—breast cancer	1.11e-05	0.000113	CcSEcCtD
Etonogestrel—Decreased appetite—Epirubicin—breast cancer	1.1e-05	0.000112	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Epirubicin—breast cancer	1.09e-05	0.000112	CcSEcCtD
Etonogestrel—Fatigue—Epirubicin—breast cancer	1.09e-05	0.000111	CcSEcCtD
Etonogestrel—Constipation—Epirubicin—breast cancer	1.08e-05	0.00011	CcSEcCtD
Etonogestrel—Pain—Epirubicin—breast cancer	1.08e-05	0.00011	CcSEcCtD
Etonogestrel—Nausea—Capecitabine—breast cancer	1.08e-05	0.00011	CcSEcCtD
Etonogestrel—Urticaria—Methotrexate—breast cancer	1.07e-05	0.00011	CcSEcCtD
Etonogestrel—Abdominal pain—Methotrexate—breast cancer	1.07e-05	0.000109	CcSEcCtD
Etonogestrel—Body temperature increased—Methotrexate—breast cancer	1.07e-05	0.000109	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.07e-05	0.000109	CcSEcCtD
Etonogestrel—Insomnia—Doxorubicin—breast cancer	1.06e-05	0.000108	CcSEcCtD
Etonogestrel—Paraesthesia—Doxorubicin—breast cancer	1.05e-05	0.000107	CcSEcCtD
Etonogestrel—Feeling abnormal—Epirubicin—breast cancer	1.04e-05	0.000106	CcSEcCtD
Etonogestrel—Somnolence—Doxorubicin—breast cancer	1.04e-05	0.000106	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Epirubicin—breast cancer	1.03e-05	0.000106	CcSEcCtD
Etonogestrel—Dyspepsia—Doxorubicin—breast cancer	1.03e-05	0.000105	CcSEcCtD
Etonogestrel—Decreased appetite—Doxorubicin—breast cancer	1.02e-05	0.000104	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Doxorubicin—breast cancer	1.01e-05	0.000103	CcSEcCtD
Etonogestrel—Fatigue—Doxorubicin—breast cancer	1.01e-05	0.000103	CcSEcCtD
Etonogestrel—Urticaria—Epirubicin—breast cancer	1.01e-05	0.000103	CcSEcCtD
Etonogestrel—Testosterone—ALB—breast cancer	1e-05	0.0036	CrCbGaD
Etonogestrel—Pain—Doxorubicin—breast cancer	1e-05	0.000102	CcSEcCtD
Etonogestrel—Constipation—Doxorubicin—breast cancer	1e-05	0.000102	CcSEcCtD
Etonogestrel—Abdominal pain—Epirubicin—breast cancer	1e-05	0.000102	CcSEcCtD
Etonogestrel—Body temperature increased—Epirubicin—breast cancer	1e-05	0.000102	CcSEcCtD
Etonogestrel—Hypersensitivity—Methotrexate—breast cancer	9.96e-06	0.000102	CcSEcCtD
Etonogestrel—Asthenia—Methotrexate—breast cancer	9.7e-06	9.91e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Doxorubicin—breast cancer	9.65e-06	9.85e-05	CcSEcCtD
Etonogestrel—Testosterone—ABCB1—breast cancer	9.59e-06	0.00343	CrCbGaD
Etonogestrel—Gastrointestinal pain—Doxorubicin—breast cancer	9.57e-06	9.78e-05	CcSEcCtD
Etonogestrel—Pruritus—Methotrexate—breast cancer	9.57e-06	9.77e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Epirubicin—breast cancer	9.32e-06	9.52e-05	CcSEcCtD
Etonogestrel—Urticaria—Doxorubicin—breast cancer	9.3e-06	9.5e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Doxorubicin—breast cancer	9.26e-06	9.45e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Doxorubicin—breast cancer	9.26e-06	9.45e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Methotrexate—breast cancer	9.25e-06	9.45e-05	CcSEcCtD
Etonogestrel—Asthenia—Epirubicin—breast cancer	9.08e-06	9.27e-05	CcSEcCtD
Etonogestrel—Pruritus—Epirubicin—breast cancer	8.95e-06	9.14e-05	CcSEcCtD
Etonogestrel—Dizziness—Methotrexate—breast cancer	8.94e-06	9.13e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Epirubicin—breast cancer	8.66e-06	8.84e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Doxorubicin—breast cancer	8.63e-06	8.81e-05	CcSEcCtD
Etonogestrel—Vomiting—Methotrexate—breast cancer	8.6e-06	8.78e-05	CcSEcCtD
Etonogestrel—Rash—Methotrexate—breast cancer	8.53e-06	8.71e-05	CcSEcCtD
Etonogestrel—Dermatitis—Methotrexate—breast cancer	8.52e-06	8.7e-05	CcSEcCtD
Etonogestrel—Headache—Methotrexate—breast cancer	8.47e-06	8.65e-05	CcSEcCtD
Etonogestrel—Asthenia—Doxorubicin—breast cancer	8.4e-06	8.58e-05	CcSEcCtD
Etonogestrel—Dizziness—Epirubicin—breast cancer	8.37e-06	8.54e-05	CcSEcCtD
Etonogestrel—Pruritus—Doxorubicin—breast cancer	8.28e-06	8.46e-05	CcSEcCtD
Etonogestrel—Vomiting—Epirubicin—breast cancer	8.05e-06	8.22e-05	CcSEcCtD
Etonogestrel—Nausea—Methotrexate—breast cancer	8.03e-06	8.2e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Doxorubicin—breast cancer	8.01e-06	8.18e-05	CcSEcCtD
Etonogestrel—Rash—Epirubicin—breast cancer	7.98e-06	8.15e-05	CcSEcCtD
Etonogestrel—Dermatitis—Epirubicin—breast cancer	7.97e-06	8.14e-05	CcSEcCtD
Etonogestrel—Headache—Epirubicin—breast cancer	7.93e-06	8.09e-05	CcSEcCtD
Etonogestrel—Dizziness—Doxorubicin—breast cancer	7.74e-06	7.91e-05	CcSEcCtD
Etonogestrel—Nausea—Epirubicin—breast cancer	7.52e-06	7.67e-05	CcSEcCtD
Etonogestrel—Vomiting—Doxorubicin—breast cancer	7.44e-06	7.6e-05	CcSEcCtD
Etonogestrel—Rash—Doxorubicin—breast cancer	7.38e-06	7.54e-05	CcSEcCtD
Etonogestrel—Dermatitis—Doxorubicin—breast cancer	7.38e-06	7.53e-05	CcSEcCtD
Etonogestrel—Headache—Doxorubicin—breast cancer	7.34e-06	7.49e-05	CcSEcCtD
Etonogestrel—Nausea—Doxorubicin—breast cancer	6.95e-06	7.1e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—NOTCH4—breast cancer	5.37e-06	0.000116	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—SIRT1—breast cancer	5.36e-06	0.000116	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GZMB—breast cancer	5.34e-06	0.000115	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—SMAD4—breast cancer	5.29e-06	0.000114	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SPP1—breast cancer	5.29e-06	0.000114	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—VDR—breast cancer	5.28e-06	0.000114	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ERBB3—breast cancer	5.23e-06	0.000113	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—FGFR2—breast cancer	5.22e-06	0.000113	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AGTR2—breast cancer	5.18e-06	0.000112	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL2—breast cancer	5.18e-06	0.000112	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—NCOR1—breast cancer	5.14e-06	0.000111	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTHLH—breast cancer	5.13e-06	0.000111	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BMP2—breast cancer	5.13e-06	0.000111	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CHST9—breast cancer	5.08e-06	0.000109	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TERT—breast cancer	5.02e-06	0.000108	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—H2AFX—breast cancer	5.01e-06	0.000108	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EDNRB—breast cancer	4.96e-06	0.000107	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PGR—breast cancer	4.91e-06	0.000106	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—THBS1—breast cancer	4.89e-06	0.000105	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—FGFR1—breast cancer	4.87e-06	0.000105	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—ERCC2—breast cancer	4.83e-06	0.000104	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—COX11—breast cancer	4.81e-06	0.000104	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HIF1A—breast cancer	4.8e-06	0.000103	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—LEP—breast cancer	4.68e-06	0.000101	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FLT1—breast cancer	4.67e-06	0.000101	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF3—breast cancer	4.65e-06	0.0001	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SQSTM1—breast cancer	4.65e-06	0.0001	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CAV1—breast cancer	4.64e-06	0.0001	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—JAG1—breast cancer	4.59e-06	9.89e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KDR—breast cancer	4.59e-06	9.89e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PARP1—breast cancer	4.57e-06	9.85e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NOTCH3—breast cancer	4.57e-06	9.85e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CALCA—breast cancer	4.51e-06	9.73e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ESR1—breast cancer	4.47e-06	9.64e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—RPS6—breast cancer	4.46e-06	9.61e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF4—breast cancer	4.42e-06	9.54e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—FN1—breast cancer	4.42e-06	9.52e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCR4—breast cancer	4.41e-06	9.5e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL12—breast cancer	4.41e-06	9.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CDA—breast cancer	4.4e-06	9.49e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SHMT1—breast cancer	4.4e-06	9.49e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NFKBIA—breast cancer	4.36e-06	9.41e-05	CbGpPWpGaD
Etonogestrel—ESR1—Generic Transcription Pathway—MYC—breast cancer	4.36e-06	9.4e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PAK1—breast cancer	4.33e-06	9.33e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NOTCH1—breast cancer	4.32e-06	9.32e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TCF7L2—breast cancer	4.25e-06	9.16e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLCO1B1—breast cancer	4.24e-06	9.14e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC2A5—breast cancer	4.24e-06	9.14e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KIT—breast cancer	4.23e-06	9.11e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CG—breast cancer	4.23e-06	9.11e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—APC—breast cancer	4.23e-06	9.11e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGF—breast cancer	4.18e-06	9.01e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HSP90AA1—breast cancer	4.1e-06	8.84e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NOTCH2—breast cancer	4.1e-06	8.84e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—APRT—breast cancer	4.09e-06	8.82e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PRL—breast cancer	3.99e-06	8.6e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AGTR1—breast cancer	3.99e-06	8.6e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—BRAF—breast cancer	3.97e-06	8.57e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—STK11—breast cancer	3.93e-06	8.47e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ADAM10—breast cancer	3.93e-06	8.47e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—NOTCH1—breast cancer	3.9e-06	8.41e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PLG—breast cancer	3.88e-06	8.38e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IGF1—breast cancer	3.87e-06	8.34e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—AKT2—breast cancer	3.87e-06	8.34e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ESRRA—breast cancer	3.85e-06	8.3e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ANGPTL4—breast cancer	3.85e-06	8.3e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF10—breast cancer	3.82e-06	8.24e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CD—breast cancer	3.71e-06	8.01e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PDGFA—breast cancer	3.69e-06	7.95e-05	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—MAPK3—breast cancer	3.68e-06	7.93e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SERPINE1—breast cancer	3.67e-06	7.92e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HADHB—breast cancer	3.65e-06	7.86e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GPI—breast cancer	3.65e-06	7.86e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFBR2—breast cancer	3.63e-06	7.84e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ITPR1—breast cancer	3.58e-06	7.71e-05	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—MYC—breast cancer	3.58e-06	7.71e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB4—breast cancer	3.55e-06	7.66e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—STAT5A—breast cancer	3.55e-06	7.66e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MMP3—breast cancer	3.55e-06	7.66e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NOS3—breast cancer	3.51e-06	7.56e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ALDH7A1—breast cancer	3.48e-06	7.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ALDH1A1—breast cancer	3.48e-06	7.5e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SMAD4—breast cancer	3.44e-06	7.42e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IGF1R—breast cancer	3.42e-06	7.37e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HES1—breast cancer	3.36e-06	7.24e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NCOR1—breast cancer	3.34e-06	7.2e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PLA2G4A—breast cancer	3.34e-06	7.2e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—FHL2—breast cancer	3.34e-06	7.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NME1—breast cancer	3.34e-06	7.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PHGDH—breast cancer	3.34e-06	7.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—UMPS—breast cancer	3.34e-06	7.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ADSL—breast cancer	3.34e-06	7.19e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MDM2—breast cancer	3.33e-06	7.18e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—SERPINE1—breast cancer	3.32e-06	7.15e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—RAF1—breast cancer	3.32e-06	7.15e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CSF2—breast cancer	3.3e-06	7.12e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF1—breast cancer	3.3e-06	7.12e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—RELA—breast cancer	3.3e-06	7.12e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ERBB2—breast cancer	3.28e-06	7.08e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NRG1—breast cancer	3.28e-06	7.07e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—LDHB—breast cancer	3.27e-06	7.05e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—BRIP1—breast cancer	3.27e-06	7.05e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HPSE—breast cancer	3.27e-06	7.05e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—H2AFX—breast cancer	3.25e-06	7.02e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MTOR—breast cancer	3.24e-06	6.98e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CB—breast cancer	3.24e-06	6.98e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—E2F1—breast cancer	3.23e-06	6.97e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CXCL8—breast cancer	3.11e-06	6.71e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SPP1—breast cancer	3.11e-06	6.7e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HMMR—breast cancer	3.1e-06	6.69e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA3—breast cancer	3.1e-06	6.69e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ABCC1—breast cancer	3.1e-06	6.69e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB3—breast cancer	3.07e-06	6.62e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGFR2—breast cancer	3.07e-06	6.61e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDKN1B—breast cancer	3.04e-06	6.55e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PPARGC1B—breast cancer	3e-06	6.48e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CASP3—breast cancer	2.98e-06	6.42e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL2—breast cancer	2.97e-06	6.41e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TERT—breast cancer	2.94e-06	6.35e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CCND1—breast cancer	2.9e-06	6.25e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—JUN—breast cancer	2.89e-06	6.24e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CTNNB1—breast cancer	2.87e-06	6.19e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGFR1—breast cancer	2.86e-06	6.16e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA4—breast cancer	2.84e-06	6.12e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CA9—breast cancer	2.84e-06	6.12e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HIF1A—breast cancer	2.82e-06	6.07e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MMP9—breast cancer	2.81e-06	6.07e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDKN1A—breast cancer	2.8e-06	6.05e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PTEN—breast cancer	2.8e-06	6.03e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA2—breast cancer	2.76e-06	5.96e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GPX2—breast cancer	2.76e-06	5.96e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—LEP—breast cancer	2.75e-06	5.93e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MAPK8—breast cancer	2.74e-06	5.9e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GPX4—breast cancer	2.73e-06	5.89e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SULT1A1—breast cancer	2.73e-06	5.89e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CAV1—breast cancer	2.72e-06	5.87e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KDR—breast cancer	2.69e-06	5.81e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—IDH1—breast cancer	2.67e-06	5.75e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA1—breast cancer	2.67e-06	5.75e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NAT2—breast cancer	2.64e-06	5.69e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SRC—breast cancer	2.59e-06	5.6e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FN1—breast cancer	2.59e-06	5.59e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NFKBIA—breast cancer	2.56e-06	5.52e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NOTCH1—breast cancer	2.54e-06	5.47e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—VEGFA—breast cancer	2.53e-06	5.45e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—STAT3—breast cancer	2.5e-06	5.4e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CG—breast cancer	2.48e-06	5.35e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—APC—breast cancer	2.48e-06	5.35e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KIT—breast cancer	2.48e-06	5.35e-05	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—AKT1—breast cancer	2.48e-06	5.35e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGF—breast cancer	2.45e-06	5.29e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MAPK3—breast cancer	2.39e-06	5.16e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BRAF—breast cancer	2.33e-06	5.03e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MYC—breast cancer	2.33e-06	5.01e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TGFB1—breast cancer	2.32e-06	5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MED12—breast cancer	2.31e-06	4.99e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—DPYD—breast cancer	2.31e-06	4.99e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ALDOA—breast cancer	2.28e-06	4.91e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGFR—breast cancer	2.27e-06	4.9e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IGF1—breast cancer	2.27e-06	4.9e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AKT2—breast cancer	2.27e-06	4.89e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA3—breast cancer	2.21e-06	4.76e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC2A2—breast cancer	2.19e-06	4.73e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CD—breast cancer	2.18e-06	4.7e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MAPK3—breast cancer	2.16e-06	4.65e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SERPINE1—breast cancer	2.16e-06	4.65e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ABCG2—breast cancer	2.15e-06	4.63e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CPT1A—breast cancer	2.15e-06	4.63e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MTR—breast cancer	2.15e-06	4.63e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KRAS—breast cancer	2.15e-06	4.63e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HPGDS—breast cancer	2.11e-06	4.55e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MYC—breast cancer	2.1e-06	4.53e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HBA1—breast cancer	2.09e-06	4.52e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NOS3—breast cancer	2.06e-06	4.44e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTT1—breast cancer	2.04e-06	4.41e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ACHE—breast cancer	2.04e-06	4.41e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CA—breast cancer	1.97e-06	4.26e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MDM2—breast cancer	1.95e-06	4.21e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—RAF1—breast cancer	1.95e-06	4.2e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—RELA—breast cancer	1.94e-06	4.18e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP17A1—breast cancer	1.94e-06	4.17e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB2—breast cancer	1.93e-06	4.15e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTGS1—breast cancer	1.92e-06	4.13e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ENO1—breast cancer	1.92e-06	4.13e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TP53—breast cancer	1.91e-06	4.12e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MTOR—breast cancer	1.9e-06	4.1e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CB—breast cancer	1.9e-06	4.1e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP2D6—breast cancer	1.88e-06	4.05e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA2—breast cancer	1.84e-06	3.98e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL8—breast cancer	1.83e-06	3.94e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HRAS—breast cancer	1.83e-06	3.94e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—FASN—breast cancer	1.79e-06	3.86e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDKN1B—breast cancer	1.78e-06	3.85e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—BCHE—breast cancer	1.78e-06	3.84e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC5A5—breast cancer	1.76e-06	3.79e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CASP3—breast cancer	1.75e-06	3.77e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL6—breast cancer	1.75e-06	3.77e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL2—breast cancer	1.75e-06	3.76e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CCND1—breast cancer	1.7e-06	3.67e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC2A1—breast cancer	1.7e-06	3.66e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NQO1—breast cancer	1.7e-06	3.66e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—JUN—breast cancer	1.7e-06	3.66e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CTNNB1—breast cancer	1.68e-06	3.63e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MMP9—breast cancer	1.65e-06	3.56e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDKN1A—breast cancer	1.65e-06	3.55e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTEN—breast cancer	1.64e-06	3.54e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP1B1—breast cancer	1.63e-06	3.51e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—AKT1—breast cancer	1.61e-06	3.48e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAPK8—breast cancer	1.61e-06	3.46e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.6e-06	3.44e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA1—breast cancer	1.55e-06	3.35e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—STK11—breast cancer	1.53e-06	3.3e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP19A1—breast cancer	1.53e-06	3.3e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SRC—breast cancer	1.52e-06	3.28e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—VEGFA—breast cancer	1.48e-06	3.2e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—STAT3—breast cancer	1.47e-06	3.17e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—AKT1—breast cancer	1.46e-06	3.14e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—COMT—breast cancer	1.42e-06	3.07e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTP1—breast cancer	1.42e-06	3.06e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAPK3—breast cancer	1.4e-06	3.03e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HMOX1—breast cancer	1.4e-06	3.01e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ITPR1—breast cancer	1.39e-06	3.01e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MYC—breast cancer	1.36e-06	2.94e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFB1—breast cancer	1.36e-06	2.94e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ABCB1—breast cancer	1.34e-06	2.89e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGFR—breast cancer	1.33e-06	2.88e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TYMS—breast cancer	1.32e-06	2.84e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTM1—breast cancer	1.3e-06	2.81e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOR1—breast cancer	1.3e-06	2.81e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.3e-06	2.81e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KRAS—breast cancer	1.26e-06	2.72e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GPX1—breast cancer	1.25e-06	2.69e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP1A1—breast cancer	1.23e-06	2.66e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ERCC2—breast cancer	1.22e-06	2.64e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CA—breast cancer	1.16e-06	2.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MTHFR—breast cancer	1.15e-06	2.48e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TP53—breast cancer	1.12e-06	2.42e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HRAS—breast cancer	1.07e-06	2.31e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CAV1—breast cancer	1.06e-06	2.29e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL6—breast cancer	1.03e-06	2.21e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CG—breast cancer	9.67e-07	2.08e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AKT1—breast cancer	9.46e-07	2.04e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CD—breast cancer	8.5e-07	1.83e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ALB—breast cancer	8.39e-07	1.81e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NOS3—breast cancer	8.03e-07	1.73e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CB—breast cancer	7.41e-07	1.6e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTGS2—breast cancer	7.34e-07	1.58e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTEN—breast cancer	6.4e-07	1.38e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CA—breast cancer	4.52e-07	9.74e-06	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AKT1—breast cancer	3.69e-07	7.96e-06	CbGpPWpGaD
